Table 4 Laboratory outcome measures for the placebo group presented as average [mean (SE)] changes from baseline for the time on active therapy (weeks 24 – 48) compared with the time on placebo (weeks 0–24). Baseline values are the average of weeks – 2 and 0 for 0 – 24 week analysis and the average of weeks 20 and 24 for 24 – 48 week analysis
|  | Weeks 0–24 | Weeks 24–48 | P |
|---|---|---|---|
HTLV-I proviral loada (log10 copies/105 PBMCs) | +0.03 (0.10) | -0.09 (0.08) | 0.50 |
Total Lymphocytesb (106/L) | +148.2 (58.0) | -71.1 (63.1) | 0.02 |
CD3 Lymphocytesb (106/L) | +98.4 (63.4) | +7.0 (39.2) | 0.28 |
CD3b % | +0.2 (2.8) | +2.8 (2.0) | 0.22 |
CD4b Lymphocytes (106/L) | +32.6 (33.1) | +30.4 (46.9) | 0.97 |
CD4b % | -1.2 (0.9) | +3.6 (1.9) | 0.08 |
CD8b Lymphocytes (106/L) | +65.8 (31.3) | -23.5 (13.7) | 0.04 |
CD8b % | +1.4 (1.2) | -0.7 (1.1) | 0.16 |
CD25a % | -0.8 (1.8) | -0.2 (1.3) | 0.82 |
CD69a % | +0.4 (1.3) | -0.2 (3.0) | 0.89 |
CD71a% | -0.3 (1.0) | +0.5 (1.3) | 0.76 |
HLA-DR% | -4.85 (4.0) | +1.05 (2.3) | 0.40 |